By Alice Goodman San Diego, CA—It was a Herculean task to review 2900 abstracts from the 2013 American College of Rheumatology (ACR) annual meeting to select the studies most likely to impact clinical practice, but Arthur F. Kavanaugh, MD, Director, Center for Innovative Therapy, University of California, San Diego, and John J. Cush, MD, Director of Clinical Rheumatology, Baylor Research Institute, Dallas, TX, took up the challenge. Following are some of their best “picks,” highlighting the practical implications for patients with rheumatic diseases.
Treatment for a life long condition such as rheumatoid arthritis (RA) is a significant part of the costs incurred by patients, but costs such as travel time and associated expenditures are also substantial costs incurred by these patients.
By Frederique H. Evans, MBS The American College of Rheumatology (ACR) Committee on Rheumatology Training and Workforce Issues found ongoing regional shortages in the rheumatology workforce and highlighted potential target communities that may benefit the most from the addition of a local rheumatologist, according to a recent report in the December 2013 issue of Arthritis & Rheumatism (American College of Rheumatology Committee on Rheumatology Training and Workforce Issues. 2013;65:3017-3025).
My first experience with documentation outside of a hospital was at a small internal medicine office in Richmond, VA. I was a fourth-year medical student, and the supervising internist ran a small, but very nice office near Stuart Circle.
By Phoebe Starr San Diego, CA—Apremilast, a first-in-class oral targeted phosphodiesterase-4 inhibitor, achieved rapid, sustained clinically meaningful resolution of oral ulcers in patients with Behçet’s disease. Apremilast also reduced disease activity and improved patients’ quality of life (QOL) and pain compared with placebo.
Washington, DC—Researchers have customized a software suite to automatically determine the disease severity in patients with rheumatoid arthritis (RA) based on information from their electronic medical records (EMRs). This is a solid first step toward streamlining and individualizing diagnosis and treatment of this condition, according to the investigators.
B-Cell Depletion Matches TNF Inhibition as Switching Option for Patients with RA Who Have Failed TNF Therapy
By Charles Bankhead For patients who have failed therapy with a tumor necrosis factor (TNF) inhibitor, switching to B-cell–depleting rituximab (Rituxan) may be a similar treatment option to switching to a different anti-TNF agent in terms of control of rheumatoid arthritis (RA), according to the results of a recent multicenter trial (Gomez-Reino JJ, et al. Ann Rheum Dis. 2012;71:1861-1864).
Charlotte, NC—Although managing rheumatoid arthritis (RA) in patients who are pregnant or trying to conceive may be challenging, rheumatologists should aim to improve disease activity and pregnancy outcomes, according to Megan E. B. Clowse, MD, MPH, Associate Professor of Medicine, Director, Duke Autoimmunity in Pregnancy Registry, Duke University Medical Center, at the North Carolina Regional Association 2014 annual meeting.
Page 1 of 4
Results 1 - 10 of 34
Results 1 - 10 of 34